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Abstract
We studied the associations of a difference in linoleic acid or carbohydrate intake with plasma cholesterol levels and risk of CHD in a
prospective cohort study in the Netherlands. Data on diet (FFQ) and plasma total and HDL-cholesterol were available at baseline
(1993–7) of 20 069 men and women, aged 20–65 years, who were initially free of CVD. Incidence of CHD was assessed through
linkage with mortality and morbidity registers. During an average of 10 years of follow-up, 280 CHD events occurred. The intake of linoleic
acid ranged from 3·6 to 8·0 % of energy (en%), whereas carbohydrate intake ranged from 47·6 to 42·5 en% across quintiles of linoleic acid
intake. Linoleic acid intake was inversely associated with total cholesterol and HDL-cholesterol in women but not in men. Linoleic
acid intake was not associated with the ratio of total to HDL-cholesterol. No association was observed between linoleic acid intake
and CHD incidence, with hazard ratios varying between 0·83 and 1·00 (all P.0·05) compared to the bottom quintile. We conclude that
a 4–5 en% difference in linoleic acid or carbohydrate intake did not translate into either a different ratio of total to HDL-cholesterol or
a different CHD incidence.
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Linoleic acid (18 : 2n-6) is an essential PUFA, and the
main fatty acid of the n-6 PUFA family. A linoleic acid
intake of 2 % of energy (en%)/d is enough to prevent
deficiency(1). Worldwide, the daily intake ranges from 3 en%
(India) to 10 en% (Israel)(2,3). In the Netherlands, the average
linoleic acid intake is 5–6 en% (approximately 14 g/d)(4–6).
n-6 PUFA currently contribute 85–90 % of total PUFA intake,
largely due to a high consumption of linoleic acid-rich
vegetable oils(7).
In 2009, the American Heart Association summarised the
scientific evidence on the association between n-6 PUFA
and CVD and advised the consumption of 5–10 en% of n-6
PUFA per d(8). n-6 PUFA have a favourable effect on
LDL-cholesterol and the ratio of total to HDL-cholesterol(9).
The positive effects of PUFA on CHD are therefore thought
to be mainly mediated by fatty acid-induced changes in
serum lipid levels. The total to HDL-cholesterol ratio is
improved by substituting PUFA for SFA, yet also by substitut-
ing PUFA for carbohydrates(10). Furthermore, carbohydrates
also increase TAG, which are an independent risk factor for
CHD(11).
A recent meta-analysis of published prospective cohort
studies did not demonstrate a positive effect of a higher
PUFA intake in exchange with an isoenergetic amount of
SFA on CHD(12). However, another meta-analysis based on
individual data that specifically addressed the isoenergetic
exchange of SFA and PUFA showed that the replacement of
5 en% from saturated fat by PUFA was significantly associated
with a 13 % lower risk for coronary events, whereas the repla-
cement of SFA by carbohydrates showed a significant direct
association with CHD(13). It has been suggested that replace-
ment of SFA by carbohydrates, mainly refined carbohydrates,
may exacerbate atherogenic dyslipidaemia(14).
The aim of the present study was to evaluate the intake
of linoleic acid, as an isoenergetic substitute for carbohydrates,
in relation to both plasma cholesterol levels and 10-year
incidence of CHD in a population-based cohort of over 20 000
adults in the Netherlands.
*Corresponding author: J. M. Geleijnse, fax þ31 317 48 33 42, email Marianne.Geleijnse@wur.nl
Abbreviations: en%, % of energy; HR, hazard ratio; MI, myocardial infarction; MORGEN, Monitoring Project on Chronic Disease Risk Factors; Q, quintile.
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Design and study population
The ‘Monitoring Project on Risk Factors for Chronic Diseases’
(MORGEN) study is a Dutch population-based cohort of
22 654 men and women aged 20–65 years. MORGEN is a
part of the European Prospective Investigation into Cancer
and Nutrition study(15). Baseline (1993–7) information on diet,
plasma cholesterol levels, lifestyle and cardiovascular risk
factors was collected and participants were followed up for
CVD end points. The present study was conducted according
to the guidelines laid down in the Declaration of Helsinki,
and all procedures involving human subjects/patients were
approved by the Medical Ethics Committee of TNO Prevention
and Health (Leiden, The Netherlands). Written informed
consent was obtained from all subjects.
For the present study, participants who did not provide
informed consent for vital status follow-up (n 701) were
excluded, as well as seventy-two participants without dietary
information and ninety-seven participants with extreme energy
intakes (,2094 or .18 844 kJ for women and ,3350 or
.20 938 kJ for men). Furthermore, participants with a history
of myocardial infarction (MI) or stroke at baseline were
excluded (n 442). We also excluded participants who reported
the use of serum lipid-modifying agents (n 203) or antihyper-
tensive drugs (n 887), and 180 participants with diabetes
resulting in 20 069 participants (8988 men and 11 081 women).
Dietary assessment
The habitual diet was assessed with a validated self-adminis-
tered 178-item FFQ covering the previous year(16,17). The
FFQ included foods that covered the intake of foods and
nutrients relevant to chronic disease aetiology for at least
90 % of the national mean intake. Participants indicated the
consumption of main food groups in times per d, per week,
per month, per year or as never, combined with questions
on the relative intakes of foods within food groups (seldom/
never, sometimes, often or mostly/always). Nutrient intakes
were calculated with the Dutch food composition table of
1998. For individual fatty acids, we used the table of 2001,
because the values were more complete. Total energy intake
was calculated as the sum of energy from fat, carbohydrates
and protein.
The reproducibility (estimated by two repeated measure-
ments) and the relative validity (intake assessed by the FFQ
compared to intakes assessed by 12-monthly 24-h recalls) of
the FFQ for food groups and some nutrients were assessed
among 121 Dutch men and women(16,17). The Spearman
rank correlations for the reproducibility of the FFQ after
6 months for total energy intake were 0·90 for men and 0·80
for women. Rank correlations were 0·83 and 0·77 for fat,
0·86 and 0·75 for protein and 0·91 and 0·85 for carbohydrates,
in men and women, respectively. The relative validity of the
FFQ for total energy intake was 0·77 for men and 0·62 for
women. Rank correlations were 0·74 and 0·63 for fat, 0·68
and 0·56 for protein and 0·75 and 0·69 for carbohydrates,
in men and women, respectively.
Plasma lipid measurements
Total cholesterol and HDL-cholesterol were measured in non-
fasting EDTA plasma at the Lipid Reference Laboratory of the
Erasmus Medical Center, Rotterdam, using enzymic methods.
Total cholesterol was measured using an enzymic method;
HDL-cholesterol was determined in the supernatant after
precipitation of apoB-containing lipoproteins with phospho-
tungstic acid/MgCl2. Performance for enzymatic total and
HDL-cholesterol measurements fulfilled the National Choles-
terol Education Program recommendations throughout the
study period(18).
Mortality and morbidity
Vital status was checked through linkage with the national
population register. Participants were followed up for the
occurrence of CHD through linkage with Statistics Netherlands
for cause-specific mortality. Information on non-fatal events
was provided by the national hospital discharge register
based on a validated probabilistic linkage method described
in more detail elsewhere(19). It has been shown that on the
national level, data from the Dutch hospital discharge register
can be uniquely matched to a single person for at least 88 % of
the hospital admissions(19). Incident CHD included fatal CHD
(I20–I25), fatal and non-fatal cardiac arrest (I46) and non-fatal
MI (I21–I22) according to the International Classification of
Diseases, 10th revision (WHO). For hospital admissions and
for causes of death coded until 1 January 1996, corresponding
International Classification of Diseases, 9th revision codes
were used. Participants were followed up until death, incident
CHD, date of loss-to-follow-up due to emigration out of the
Netherlands (n 693) or 1 January 2006, whichever came first.
Other baseline characteristics
Body weight, height and blood pressure were measured by
trained research nurses. Self-administered questionnaires
were used to assess the presence of diabetes, MI and stroke
at baseline, medication use, parental history of MI, educational
level and cigarette smoking(20). Alcohol intake (based on the
FFQ) was calculated in glasses/d. Baseline physical activity
was assessed with a validated questionnaire in 76 % of the
cohort who were enrolled between 1994 and 1997(21). For
this subset, we calculated whether participants were engaged
in activities with a metabolic equivalent score $4 (yes/no).
Cycling (yes/no) and sports (yes/no) were previously shown
to be significantly inversely related to CVD incidence in this
population(22).
Statistical analysis
Participants’ characteristics by quintiles of linoleic acid intake
expressed as en% are presented as mean values and standard
deviations, medians with interquartile ranges or percentages.
Correlations between the energy-adjusted intakes of different
types of fatty acids were assessed using the Spearman rank
correlation test.

















Mean plasma levels of total and HDL-cholesterol and the
ratio of total to HDL-cholesterol by quintiles of linoleic acid
intake (en%) were computed using general linear models.
P for trend values of plasma cholesterol levels were calculated
based on the continuous distribution of linoleic acid intake.
We used Cox proportional hazards models to estimate relative
risks for the incidence of CHD across quintiles of linoleic acid
intake at baseline. Hazard ratios (HR) with 95 % CI were
obtained using the bottom quintile of linoleic acid intake as
the reference category. The proportional hazards assumption
was tested and not rejected based on Schoenfeld residuals
and visual inspection. In model 1, we adjusted for total
energy intake (kJ/d), age and sex. In model 2, we additionally
adjusted for BMI (kg/m2), alcohol intake (glasses/d), current
cigarette smoking, high educational level (completed higher
vocational training or university) (yes/no) and parental history
of premature CHD (MI of father before the age of 55 years or
MI of mother before the age of 65 years) (yes/no). In model 3,
we added intakes of fibre (g/d), protein, SFA, cis-MUFA, trans-
fat and PUFA other than linoleic acid (all in en%). The
estimated HR of the full model can be interpreted as an iso-
energetic replacement of carbohydrates with linoleic acid.
We assessed the impact of adjustments for systolic blood
pressure, the total to HDL-cholesterol ratio and physical
activity. Effect modification was evaluated for age and sex
by adding product terms to the models. All statistical analyses
were performed with SAS (version 9.1; SAS Institute, Inc.,




Participants were on average 41·5 (SD 11·1) years at baseline,
and 45 % were male. The average intake of linoleic acid was
13·9 (SD 5·9) g/d or 5·6 (SD 1·6) en%. Linoleic acid comprised
79 % of total PUFA intake. During 8–13 years of follow-up
(median 10·5 years), 199 men and 81 women experienced a
CHD event, of which 19 % was a fatal event.
The main sources of linoleic acid intake were margarines
(21 %), oils (13 %), bread (12 %), nuts (10 %), pork meat
(10 %) and sauces (9 %). Mean linoleic acid intake more than
doubled across quintiles (Q), from 3·6 en% in Q1 to 8·0 en%
in Q5. SFA and trans-fatty acids did not differ across quintiles,
and carbohydrate intake decreased from 47·6 to 42·5 en%.
Polysaccharides did not differ between quintiles, whereas
mono- and disaccharides decreased from 25 to 19 en%
(Table 1). The Spearman correlations with linoleic acid were
0·98 for total PUFA, 0·43 for total fat, 0·32 for cis-MUFA and
20·35 for mono- and disaccharides.
Linoleic acid, plasma lipid levels and CHD
We observed interaction of sex on the association between
linoleic acid intake and cholesterol levels. P-values for inter-
action were ,0·0001 for total cholesterol, 0·01 for HDL-
cholesterol and 0·37 for the ratio of total to HDL-cholesterol.
In women, linoleic acid intakes were inversely associated
with plasma total cholesterol levels in the fully adjusted
model, with a mean total cholesterol level of 5·28 mmol/l
(2042 mg/l) in Q1 and 5·14 mmol/l (1988 mg/l) in Q5
(P-trend ,0·0001). In men, however, linoleic acid intake
was not associated with total cholesterol. Linoleic acid intakes
were inversely associated with plasma HDL-cholesterol across
quintiles, in both men and women, although this inverse
association did not reach statistical significance in men.
Linoleic acid intake was inversely, but not significantly,
associated with the ratio of total to HDL-cholesterol in
women, with ratio values between 3·65 (Q1) and 3·59 (Q5),
whereas a positive, yet also non-significant, association was
observed in men, with ratios varying between 4·65 (Q1) and
4·73 (Q5; Table 2).
After adjustment for potential confounders, linoleic acid
intake was not associated with incident CHD. HR varied
between 0·83 and 1·00 (all P.0·05) compared with the
bottom quintile of linoleic acid intake (Table 3). The HR of
incident CHD for a 5 % higher energy intake of linoleic acid
with a concurrent lower intake of carbohydrates was 1·01
(95 % CI 0·86, 1·19).
We observed no interaction of sex or age (#50 or .50
years) and linoleic acid intake in relation to incident CHD
(data not shown). HR (95 % CI) for incident CHD after
additional inclusion of the ratio of total to HDL-cholesterol
and systolic blood pressure in the multivariable models were
0·92 (95 % CI 0·62, 1·36), 0·82 (95 % CI 0·55, 1·24), 1·00 (95 %
CI 0·68, 1·48), 0·86 (95 % CI 0·57, 1·30) for Q2–Q5 compared
with Q1, respectively. For the subgroup with information on
physical activity (n 15 423), the full model with and without
physical activity yielded similar results (data not shown).
Models based on isoenergetic substitution with SFA did not
differ from the models based on substitution with carbo-
hydrates (data not shown).
Discussion
In this large Dutch population-based cohort, a higher linoleic
acid and concurrent lower carbohydrate intake was inversely
associated with total cholesterol and HDL-cholesterol in
women, but not in men. Linoleic acid intake was neither
related to the ratio of total to HDL-cholesterol nor to CHD
incidence.
In the present population-based study, the intakes of
saturated fat and trans-fat were similar across the quintiles
of linoleic acid intake and only carbohydrates varied between
high and low linoleic acid intake. The present data set
therefore allowed the analysis of real differences in intake
between participants instead of statistically modelling these
differences. Another strength of the present study was the
almost complete follow-up of mortality. Furthermore, the pro-
cedure of identification of non-fatal events was validated in
36 % of the participants of the present study by comparison
against the clinical registry of the Cardiology Department of
the Maastricht University Hospital. This showed a relatively
high sensitivity (84 %) and positive predictive value (97 %)

















for MI(23). In addition, we also had detailed information on
many potential confounders.
The present study also had limitations. Misclassification of
subjects for linoleic acid intake may have occurred. However,
we excluded participants with a history of MI or stroke, and
also participants who used cholesterol-lowering or blood
pressure-lowering medication, because these may have chan-
ged their diet. We therefore consider potential misclassifi-
cation at baseline to be random rather than dependent on
disease outcome. Multiple simultaneous and partly opposite
effects of diet and lifestyle on CHD incidence had to be
taken into account, including correlated types of fatty acids,
partly due to presence in the same foods. Like in any other
epidemiological study on diet and CHD, this may also have
affected results in the present study. Although we attempted
to disentangle the various possible simultaneous effects with
the present statistical models, it is impossible to completely
rule out confounding.
In the present study, linoleic acid intake was not signifi-
cantly associated with the plasma total to HDL-cholesterol
Table 1. Baseline characteristics of 20 069 Dutch men and women, aged 20–65 years, by quintiles (Q) of energy percentages of linoleic acid intake
(Mean values and standard deviations, unless indicated)
Q1 Q2 Q3 Q4 Q5
Mean SD Mean SD Mean SD Mean SD Mean SD
n 4013 4014 4014 4014 4014
Male sex (%) 45 42 43 46 48
Age (years) 41·6 11·8 40·5 11·2 40·7 10·9 41·2 10·7 43·3 10·6
PUFA
g/d 11·9 4·0 15·0 4·4 17·0 5·0 19·6 5·8 23·9 7·6
en% 4·9 0·6 6·1 0·4 6·9 0·4 7·8 0·5 9·6 1·2
Linoleic acid
g/d 8·8 3·0 11·4 3·4 13·3 3·9 15·8 4·7 20·0 6·6
en% 3·6 0·5 4·6 0·2 5·4 0·2 6·3 0·3 8·0 1·1
a-Linolenic acid
g/d 1·1 0·4 1·3 0·5 1·4 0·5 1·6 0·6 1·7 0·7
en% 0·4 0·1 0·5 0·1 0·6 0·1 0·6 0·2 0·7 0·2
Cis-MUFA
g/d 27·8 10·5 30·3 10·5 31·2 10·8 32·7 11·4 33·7 12·4
en% 11·4 2·1 12·3 2·0 12·5 2·1 12·9 2·1 13·5 2·3
TFA
g/d 3·7 1·9 3·9 1·9 3·9 1·8 3·9 1·9 3·7 1·8
en% 1·5 0·5 1·6 0·5 1·6 0·5 1·5 0·5 1·4 0·5
SFA
g/d 36·9 14·5 37·5 13·3 37·2 13·1 38·0 13·3 36·8 13·2
en% 15·1 3·0 15·1 2·5 14·9 2·4 15·0 2·3 14·7 2·3
P:S ratio 0·32 0·40 0·46 0·52 0·65
Cholesterol (mg/d) 244·0 96·8 245·8 92·1 241·8 89·9 244·2 90·2 231·3 91·0
Total fat
g/d 81·2 29·7 87·4 29·0 89·9 29·6 95·0 31·4 98·7 33·3
en% 33·3 5·2 35·3 4·5 36·1 4·5 37·6 4·4 39·4 4·5
Total carbohydrate (en%) 47·6 5·5 46·0 4·8 45·3 4·8 44·1 4·7 42·5 4·8
Mono and disaccharides (en%) 25·0 6·2 22·5 5·3 21·6 5·2 20·5 51 19·1 4·9
Polysaccharides (en%) 22·6 4·7 23·4 4·3 23·6 4·2 23·6 4·3 23·4 4·2
Fibre (g/d) 23·8 7·4 24·4 7·0 24·8 7·0 25·3 7·2 25·6 7·3
Protein (en%) 16·1 2·7 15·8 2·3 15·7 2·2 15·5 2·1 15·3 2·1
Energy intake (MJ/d)* 9·0 2·8 9·1 2·7 9·2 2·7 9·3 2·7 9·2 2·7
BMI (kg/m2) 24·9 3·8 24·9 3·9 24·9 3·8 24·8 3·7 24·9 3·9
Body weight (kg) 74·2 13·6 74·1 13·3 74·4 13·2 74·3 13·1 74·5 13·8
Current smoking (%) 35 36 36 37 39
Alcohol consumption (glasses/d)† 0·4 0·6 0·7 0·7 0·8
Interquartile range 0·1, 1·7 0·1, 1·7 0·1, 1·9 0·1, 2·0 0·1, 2·0
Highly educated (%)‡ 20 23 27 27 27
Physically active (%)§
Sports 38 38 39 38 34
Cycling 57 60 61 62 58
Parental history of MI (%) 8 8 9 10 9
SBP (mmHg) 120·4 15·5 119·8 15·5 119·3 15·3 119·3 15·0 120·7 16·3
DBP (mmHg) 76·4 10·3 76·0 10·4 75·8 10·2 75·8 10·2 76·4 10·7
Plasma total cholesterol (mmol/l) 5·3 1·0 5·3 1·0 5·2 1·0 5·3 1·0 5·3 1·1
Plasma HDL-cholesterol (mmol/l) 1·4 0·4 1·4 0·4 1·4 0·4 1·4 0·4 1·4 0·4
Total cholesterol:HDL-cholesterol 4·1 1·5 4·1 1·4 4·1 1·5 4·1 1·5 4·2 1·5
en%, % of energy; TFA, trans-fatty acids; P:S, polyunsaturated:saturated ratio; MI, myocardial infarction; SBP, systolic blood pressure; DBP, diastolic blood pressure.
* Total energy excluding alcohol intake.
† Median with interquartile range.
‡ University or higher vocation training.
§ Available for participants enrolled between 1994 and 1997 (n 15 423).

















ratio. A meta-analysis of controlled dietary intervention studies
showed that the replacement of 1 en% of carbohydrates
by PUFA would result in a reduction of the ratio of total
to HDL-cholesterol by 0·032. In observational studies of
adults between 40 and 59 years, each one unit lower total to
HDL-cholesterol ratio was associated with a 44 % lower risk
of CHD(9). In the population of the present study, derived
from controlled dietary intervention studies, the predicted
difference of the total to HDL ratio between highest and
lowest quintiles of linoleic acid intake was 20·15(10), which
corresponds to an approximately 7 % lower CHD incidence.
However, such a modest difference is difficult to detect
considering the errors in observational food intake data.
A linoleic acid intake ranging between 3·6 and 8·0 en% was
not significantly associated with incident CHD in the present
study. These results are in line with those from the cohort
Table 2. Adjusted cholesterol levels by quintiles (Q) of energy percentages of linoleic acid intake in 20 069 Dutch men and women*†
(Mean values with their standard errors)
Model 1‡ Model 2§ Model 3k
n
Median
intake (en%) Mean SE Mean SE Mean SE
Men
Total cholesterol (mmol/l)
Q1 1797 3·7 5·27 0·02 5·26 0·02 5·25 0·02
Q2 1798 4·7 5·30 0·02 5·30 0·02 5·30 0·02
Q3 1798 5·4 5·26 0·02 5·26 0·02 5·26 0·02
Q4 1798 6·3 5·33 0·02 5·34 0·02 5·35 0·02
Q5 1797 7·8 5·27 0·02 5·28 0·02 5·29 0·02
P trend 0·90 0·49 0·31
HDL-cholesterol (mmol/l)
Q1 1797 3·7 1·19 0·01 1·20 0·01 1·21 0·01
Q2 1798 4·7 1·20 0·01 1·20 0·01 1·20 0·01
Q3 1798 5·4 1·18 0·01 1·18 0·01 1·18 0·01
Q4 1798 6·3 1·19 0·01 1·19 0·01 1·18 0·01
Q5 1797 7·8 1·20 0·01 1·20 0·01 1·19 0·01
P trend 0·38 0·61 0·16
Total cholesterol:HDL-cholesterol
Q1 1797 3·7 4·72 0·04 4·70 0·03 4·65 0·04
Q2 1798 4·7 4·68 0·04 4·68 0·03 4·67 0·03
Q3 1798 5·4 4·73 0·04 4·72 0·03 4·73 0·03
Q4 1798 6·3 4·74 0·04 4·77 0·03 4·79 0·03
Q5 1797 7·8 4·69 0·04 4·70 0·03 4·73 0·04
P trend 0·68 0·78 0·06
Women
Total cholesterol (mmol/l)
Q1 2216 3·8 5·28 0·02 5·28 0·02 5·28 0·02
Q2 2216 4·6 5·29 0·02 5·28 0·02 5·28 0·02
Q3 2217 5·3 5·21 0·02 5·21 0·02 5·21 0·02
Q4 2216 6·2 5·22 0·02 5·22 0·02 5·22 0·02
Q5 2216 7·7 5·13 0·02 5·14 0·02 5·14 0·02
P trend ,0·0001 ,0·0001 ,0·0001
HDL-cholesterol (mmol/l)
Q1 2216 3·8 1·52 0·01 1·52 0·01 1·53 0·01
Q2 2216 4·6 1·52 0·01 1·53 0·01 1·53 0·01
Q3 2217 5·3 1·52 0·01 1·52 0·01 1·52 0·01
Q4 2216 6·2 1·51 0·01 1·51 0·01 1·51 0·01
Q5 2216 7·7 1·52 0·01 1·52 0·01 1·51 0·01
P trend 0·89 0·25 0·002
Total cholesterol:HDL-cholesterol
Q1 2216 3·8 3·67 0·02 3·66 0·02 3·65 0·02
Q2 2216 4·6 3·66 0·02 3·65 0·02 3·64 0·02
Q3 2217 5·3 3·62 0·02 3·62 0·02 3·62 0·02
Q4 2216 6·2 3·65 0·02 3·65 0·02 3·66 0·02
Q5 2216 7·7 3·57 0·02 3·58 0·02 3·59 0·02
P trend 0·001 0·008 0·10
en%, % of energy.
* Total cholesterol was missing for n 113 and HDL-cholesterol was missing for n 123.
† Stratified analysis was based on sex-specific quintiles of linoleic acid.
‡ Means adjusted for age, sex and total energy intake. For total cholesterol: n 8951 in men and n 11 005 in women. For HDL-cholesterol and the total:
HDL-cholesterol ratio: n 8948 in men and n 10 998 in women.
§ Means additionally adjusted for smoking, BMI, educational level, parental history of myocardial infarction and alcohol intake. For total cholesterol: n 8876
in men and n 10 909 in women. For HDL-cholesterol and the total: HDL-cholesterol ratio: n 8875 in men and n 10 902 in women.
k Means additionally adjusted for intake of dietary fibre, protein, SFA, MUFA, trans-fatty acids, PUFA other than linoleic acid. For total cholesterol: n 8876
in men and n 10 909 in women. For HDL-cholesterol and the total: HDL-cholesterol ratio: n 8875 in men and n 10 902 in women.

















studies in Finnish men(24), Danish men and women(25) and
American men(26), which also used models of isoenergetic
substitution of PUFA for carbohydrates. A similar model was
used in the Nurses’ Health Study. However, in that study
with 80 000 women (1766 events), PUFA intake, ranging
from 4·1 to 7·4 en%, was inversely associated with a 25 (95 %
CI 8, 40) % lower CHD incidence in Q5 compared to Q1(27).
Observational studies in the USA or Western Europe mostly
covered relatively small ranges of intake of 5 to 10 en%. To
find associations within this range will be complicated by
measurement error of intake in single dietary assessments(28).
Therefore, in observational studies, differences in linoleic acid
intake may not translate into the predicted, although modest,
differences in cholesterol and CHD risk.
On the basis of eight randomised trials, it has been shown
that an increase in PUFA intake of 5 % of energy was signifi-
cantly associated with a 10 % lower risk of coronary events(29).
However, this effect size was estimated from large contrasts of
PUFA intake (on average 5 v. 15 en%) between the interven-
tion and control groups. Additionally, the PUFA interventions
were mostly a combination of both a higher intake of n-6 and
n-3 PUFA, whereas in the present study, we adjusted for PUFA
other than linoleic acid. A recent meta-analysis separated the
trials in the meta-analysis of Mozaffarian et al.(29) into those
on n-6 PUFA only and those with combined n-6 and n-3
PUFA interventions. The authors(30) concluded that there
was no indication of benefit of n-6 PUFA, although this state-
ment was based on only two trials. However, it is clear from
the information presented in that paper that the effect of a
5 en% difference in n-6 PUFA intake is less than the 10 %
difference in CHD incidence calculated from the dietary inter-
ventions for total PUFA.
In conclusion, in this large population-based study in the
Netherlands, a 4–5 en% difference in linoleic acid or carbo-
hydrate intake did not translate into either a different ratio of
plasma total to HDL-cholesterol or a different CHD incidence.
Acknowledgements
This work was supported by an unrestricted grant from
the Product Board for Margarine, Fats and Oils, Rijswijk,
The Netherlands to the Wageningen University. The Monitor-
ing Project on Risk Factors for Chronic Diseases (MORGEN)
study was financially supported by the Ministry of Health,
Welfare and Sport of the Netherlands, the National Institute
for Public Health and the Environment, Bilthoven, The Nether-
lands and the Europe Against Cancer Program of the
European Union. J. M. G. has received unrestricted grants from
the Alpro Foundation, Belgium and from the Product Board
for Margarine, Fats and Oils. J. M. G. and D. K. have received
research grants from the Netherlands Heart Foundation, the
NIH and Unilever Research and Development, The Nether-
lands, for the Alpha Omega Trial on n-3 fatty acids and
CVD. The other authors report no conflicts of interest. J. G.,
J. M. G., D. K. and W. M. M. V. designed the research; J. M.
A. B. and W. M. M. V. provided the data; J. G. analysed data
and performed statistical analyses; J. G. drafted the paper;
J. G., J. M. G. and D. K. had primary responsibility for final
content. All authors read and approved the final manuscript.
References
1. Food and Agriculture Organization/World Health Organiz-
ation (2008) Joint FAO/WHO Expert Consultation. Interim
Summary and Conclusions and Dietary Recommendations
on Total Fat & Fatty Acids. Geneva: FAO/WHO.
2. Elmadfa I & Kornsteiner M (2009) Dietary fat intake – a
global perspective. Ann Nutr Metab 54, Suppl. 1, 8–14.
3. Kark JD, Kaufmann NA, Binka F, et al. (2003) Adipose tissue
n-6 fatty acids and acute myocardial infarction in a popu-
lation consuming a diet high in polyunsaturated fatty acids.
Am J Clin Nutr 77, 796–802.
4. Voorlichtingsbureau voor de Voeding (1993) Zo eet Neder-
land: Resultaten Van de Voedselconsumptiepeiling 1992
(Dutch National Food Consumption Survey of 1992).
The Hague: Voorlichtingsbureau voor de Voeding.
5. Voedingscentrum (1998) Zo eet Nederland: Resultaten van
de Voedselconsumptiepeiling 1997–1998. (Dutch National
Food Consumption Survey of 1997–1998). The Hague: Voe-
dingscentrum.
6. Elmadfa I & Kornsteiner M (2009) Fats and fatty acid require-
ments for adults. Ann Nutr Metab 55, 56–75.
7. Meyer BJ, Mann NJ, Lewis JL, et al. (2003) Dietary intakes
and food sources of omega-6 and omega-3 polyunsaturated
fatty acids. Lipids 38, 391–398.
Table 3. Associations of linoleic acid intake* with incident CHD in 20 069 Dutch men and women
(Numbers, hazard ratios and 95 % confidence intervals)
Model 1† Model 2‡ Model 3§
n
Median
intake (en%) Cases (n) HR 95 % CI HR 95 % CI HR 95 % CI
Q1 4013 3·7 61 1·0 (ref) 1·0 (ref) 1·0 (ref)
Q2 4014 4·7 50 0·95 0·65, 1·38 0·93 0·63, 1·35 0·90 0·61, 1·33
Q3 4014 5·4 46 0·86 0·59, 1·26 0·86 0·58, 1·27 0·83 0·56, 1·24
Q4 4014 6·2 61 1·03 0·72, 1·47 1·04 0·73, 1·50 1·00 0·68, 1·47
Q5 4014 7·7 62 0·91 0·64, 1·29 0·94 0·65, 1·34 0·90 0·60, 1·36
Per 2 % 1·00 0·87, 1·15 1·02 0·89, 1·17 1·01 0·86, 1·19
en%, % of energy; HR, hazard ratio; Q, quintile.
* Values are HR with 95 % CI in quintiles (Q1–Q5) of linoleic acid intake, using Q1 as the reference category.
† Adjusted for age, sex and total energy intake (n 20 069).
‡ Additionally adjusted for smoking, BMI, educational level, parental history of myocardial infarction and alcohol intake (n 19 896).
§ Additionally adjusted for dietary fibre, protein, SFA, cis-MUFA, trans-fatty acids and PUFA other than linoleic acid (n 19 896).

















8. Harris WS, Mozaffarian D, Rimm E, et al. (2009) Omega-6
fatty acids and risk for cardiovascular disease: a science
advisory from the American Heart Association Nutrition
Subcommittee of the Council on Nutrition, Physical Activity,
and Metabolism; Council on Cardiovascular Nursing; and
Council on Epidemiology and Prevention. Circulation 119,
902–907.
9. Lewington S, Whitlock G, Clarke R, et al. (2007) Blood
cholesterol and vascular mortality by age, sex, and blood
pressure: a meta-analysis of individual data from 61 prospec-
tive studies with 55,000 vascular deaths. Lancet 370,
1829–1839.
10. Mensink RP, Zock PL, Kester AD, et al. (2003) Effects of diet-
ary fatty acids and carbohydrates on the ratio of serum total
to HDL cholesterol and on serum lipids and apolipoproteins:
a meta-analysis of 60 controlled trials. Am J Clin Nutr 77,
1146–1155.
11. Hokanson JE & Austin MA (1996) Plasma triglyceride level
is a risk factor for cardiovascular disease independent of
high-density lipoprotein cholesterol level: a meta-analysis
of population-based prospective studies. J Cardiovasc Risk
3, 213–219.
12. Siri-Tarino PW, Sun Q, Hu FB, et al. (2010) Meta-analysis
of prospective cohort studies evaluating the association of
saturated fat with cardiovascular disease. Am J Clin Nutr
91, 535–546.
13. Jakobsen MU, O’Reilly EJ, Heitmann BL, et al. (2009) Major
types of dietary fat and risk of coronary heart disease:
a pooled analysis of 11 cohort studies. Am J Clin Nutr 89,
1425–1432.
14. Siri-Tarino PW, Sun Q, Hu FB, et al. (2010) Saturated fat,
carbohydrate, and cardiovascular disease. Am J Clin Nutr
91, 502–509.
15. Riboli E & Kaaks R (1997) The EPIC Project: rationale and
study design. European Prospective Investigation into
Cancer and Nutrition. Int J Epidemiol 26, Suppl. 1, S6–S14.
16. Ocke´ MC, Bueno-de-Mesquita HB, Goddijn HE, et al. (1997)
The Dutch EPIC food frequency questionnaire. I. Description
of the questionnaire, and relative validity and reproducibility
for food groups. Int J Epidemiol 26, Suppl. 1, S37–S48.
17. Ocke´ MC, Bueno-de-Mesquita HB, Pols MA, et al. (1997)
The Dutch EPIC food frequency questionnaire. II. Relative
validity and reproducibility for nutrients. Int J Epidemiol
26, Suppl. 1, S49–S58.
18. Houterman S, Verschuren WM, Oomen CM, et al. (2001)
Trends in total and high density lipoprotein cholesterol
and their determinants in The Netherlands between 1993
and 1997. Int J Epidemiol 30, 1063–1070.
19. De Bruin A, De Bruin EI, Gast A, et al. (2003) Linking Data
of National Ambulant Register and GBA Data: Methods,
Results and Quality Research (in Dutch). Koppeling van
LMR- en GBA gegevens: methode, resultaten en kwaliteitson-
derzoek. Voorburg/Heerlen: Statistics Netherlands.
20. Verschuren WM, Blokstra A, Picavet HS, et al. (2008) Cohort
profile: the Doetinchem Cohort Study. Int J Epidemiol 37,
1236–1241.
21. Pols M, Peeters P, Ocke´ M, et al. (1997) Estimation of repro-
ducibility and relative validity of the questions included in
the EPIC Physical Activity Questionnaire. Int J Epidemiol
26, 181S–189S.
22. Hoevenaar-Blom MP, Wanda Wendel-Vos GC, Spijkerman
AM, et al. (2010) Cycling and sports, but not walking, are
associated with 10-year cardiovascular disease incidence:
the MORGEN Study. Eur J Cardiovasc Prev Rehabil 18,
41–47.
23. Merry AH, Boer JM, Schouten LJ, et al. (2009) Validity of
coronary heart diseases and heart failure based on hospital
discharge and mortality data in the Netherlands using
the cardiovascular registry Maastricht cohort study. Eur J
Epidemiol 24, 237–247.
24. Pietinen P, Ascherio A, Korhonen P, et al. (1997) Intake of
fatty acids and risk of coronary heart disease in a cohort
of Finnish men. The Alpha-Tocopherol, Beta-Carotene
Cancer Prevention Study. Am J Epidemiol 145, 876–887.
25. Jakobsen MU, Overvad K, Dyerberg J, et al. (2004)
Dietary fat and risk of coronary heart disease: possible
effect modification by gender and age. Am J Epidemiol
160, 141–149.
26. Mozaffarian D, Ascherio A, Hu FB, et al. (2005) Interplay
between different polyunsaturated fatty acids and risk of
coronary heart disease in men. Circulation 111, 157–164.
27. Oh K, Hu FB, Manson JE, et al. (2005) Dietary fat intake
and risk of coronary heart disease in women: 20 years of
follow-up of the nurses’ health study. Am J Epidemiol 161,
672–679.
28. Jacobs DR Jr, Anderson JT & Blackburn H (1979) Diet and
serum cholesterol: do zero correlations negate the relation-
ship? Am J Epidemiol 110, 77–87.
29. Mozaffarian D, Micha R & Wallace S (2010) Effects on
coronary heart disease of increasing polyunsaturated fat in
place of saturated fat: a systematic review and meta-analysis
of randomized controlled trials. PLoS Med 7, e1000252.
30. Ramsden CE, Hibbeln JR, Majchrzak SF, et al. (2010) n-6
Fatty acid-specific and mixed polyunsaturate dietary inter-
ventions have different effects on CHD risk: a meta-analysis
of randomised controlled trials. Br J Nutr 104, 1586–1600.
Linoleic acid, cholesterol and coronary disease 7
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
